國藥科技股份(08156.HK)前三季度收入增長357% 將尋求口罩更大規模生產
格隆匯5月14日丨國藥科技股份(08156.HK)公佈，截至2020年3月31日止9個月，公司收入9855萬港元，同比增長357%；毛利2305萬港元，同比增長44.5%。
在互聯網+大健康業務方面，隨着集團與珠海華髮合作的深入，下一步或考慮與其建立大健康產業鏈方面的業務聯繫，為珠海華髮在包括醫用口罩生產等在內的大健康領域方面的業務發展提供技術支撐和渠道支持，圍繞股權投資、技術創新、研發生產、渠道推廣、市場銷售等方面開展廣泛合作，促進雙方業務發展。此外，珠海華髮亦計劃就其金融板塊業務與集團在聯合營銷、協同項目、客户推薦等方面進行合作，為集團提供資本市場金融服務。
集團在發展口罩生產業務方面雄心勃勃，尋求實現更大規模生產的可能性。於回顧期後，第二、第三間口罩工廠的籌備、建設工作穩步推進。第二間口罩工廠擁有更大的佔地面積及更大數量的生產設備，亦計劃自設檢驗實驗室、對公眾開放的參觀區域及陳列室，提升生產透明度、提升公眾信心。目前，第二間工廠的第一期工程已完成，設置完畢的車間內的設備進入試產階段；而第三間工廠的無塵車間已經完成並進入設備調試階段。
於回顧期後，集團與騰訊控股有限公司在醫療物資採購與服務領域建立為期三年的戰略合作關係，有助於拓寬集團醫用物資的銷售渠道，亦提升集團的戰略商業網絡層次。
未來中短期內，集團將繼續着力於醫療防護物資的生產及銷售業務。新冠疫情肆虐的特殊時期，集團憑藉公司背景順暢聯結內地與香港市場，充分利用合作伙伴在商品採購、分銷、報關、報檢、運輸等方面的優勢高效運送物資；亦尋求打通境外供貨渠道的機會，將符合其他國家或地區醫用物資銷售標準的產品銷往需求終端市場，境內外雙線驅動，加足動力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
